| Primary |
| Drug Use For Unknown Indication |
30.8% |
| Impetigo |
23.5% |
| Staphylococcal Infection |
10.0% |
| Wound |
6.2% |
| Skin Infection |
5.0% |
| Infection |
4.7% |
| Rash |
3.6% |
| Open Wound |
2.6% |
| Wound Infection |
2.6% |
| Skin Lesion |
1.7% |
| Blister |
1.4% |
| Laceration |
1.4% |
| Product Used For Unknown Indication |
1.2% |
| Infection Prophylaxis |
0.9% |
| Prophylaxis |
0.9% |
| Bacterial Infection |
0.7% |
| Biopsy |
0.7% |
| Cellulitis |
0.7% |
| Eczema |
0.7% |
| Folliculitis |
0.7% |
|
| Application Site Irritation |
17.9% |
| Burning Sensation |
14.6% |
| Pain |
10.2% |
| Application Site Pain |
9.8% |
| Drug Ineffective |
6.7% |
| Rash |
6.5% |
| Skin Irritation |
5.2% |
| Hypersensitivity |
4.0% |
| Dermatitis Contact |
3.8% |
| Pruritus |
3.5% |
| Swelling |
2.9% |
| Erythema |
2.5% |
| Thermal Burn |
2.5% |
| Application Site Pruritus |
2.1% |
| Screaming |
1.5% |
| Skin Burning Sensation |
1.5% |
| Dermatitis |
1.3% |
| Infection |
1.3% |
| Lip Swelling |
1.3% |
| Rash Papular |
1.3% |
|
| Secondary |
| Product Used For Unknown Indication |
37.5% |
| Breast Cancer |
25.0% |
| Infection |
25.0% |
| Rash |
12.5% |
|
| Malaise |
33.3% |
| Rash |
33.3% |
| Skin Infection |
33.3% |
|
| Concomitant |
| Fibromyalgia |
10.0% |
| Pain |
10.0% |
| Acne |
5.0% |
| Antiallergic Therapy |
5.0% |
| Antibiotic Therapy |
5.0% |
| Arthralgia |
5.0% |
| Arthropod Bite |
5.0% |
| Asthma |
5.0% |
| Bronchitis |
5.0% |
| Contraception |
5.0% |
| Growth Of Eyelashes |
5.0% |
| Herpes Virus Infection |
5.0% |
| Hypersensitivity |
5.0% |
| Hypertension |
5.0% |
| Menstrual Disorder |
5.0% |
| Pneumonia |
5.0% |
| Skin Wrinkling |
5.0% |
| Smoking Cessation Therapy |
5.0% |
|
| Weight Decreased |
17.6% |
| Cataract |
11.8% |
| Death |
11.8% |
| Urinary Tract Infection |
11.8% |
| Anhedonia |
5.9% |
| Atelectasis |
5.9% |
| Gait Disturbance |
5.9% |
| Skin Haemorrhage |
5.9% |
| Vascular Occlusion |
5.9% |
| Visual Impairment |
5.9% |
| Wrong Technique In Drug Usage Process |
5.9% |
| X-ray Limb Abnormal |
5.9% |
|
